We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Ocugen Inc
135 own
88 watching
Current Price
$0.4
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
97.52M
52-Week High
2.08900
52-Week Low
0.39000
Average Volume
1.12M
Dividend Yield
--
P/E Ratio
--
Market Capitalization97.52M52-Week High2.0890052-Week Low0.39000Average Volume1.12MDividend Yield--P/E Ratio--What does the Ocugen Inc do?
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More
How much money does Ocugen Inc make?
News & Events about Ocugen Inc.
Globe Newswire
2 months ago
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Zolmax
3 months ago
Ocugen, Inc. (NASDAQ:OCGN Get Rating) Director Junge Zhang purchased 200,278 shares of the companys stock in a transaction on Wednesday, June 14th. The stock was bought at an average price of $0.50 per share, for a total transaction of $100,139.00. Following the completion of the purchase, the ...
Globe Newswire
4 months ago
Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for the ...
Globe Newswire
5 months ago
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live ...
Globe Newswire
5 months ago
Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes71.4% (5/7) of OCU400 ...
Frequently Asked Questions
Frequently Asked Questions
What is Ocugen Inc share price today?
Can Indians buy Ocugen Inc shares?
How can I buy Ocugen Inc shares from India?
Can Fractional shares of Ocugen Inc be purchased?
What are the documents required to start investing in Ocugen Inc stocks?
What is today’s traded volume of Ocugen Inc?
What is today’s market capitalisation of Ocugen Inc?
What is the 52-Week High and Low Range of Ocugen Inc?
What percentage is Ocugen Inc down from its 52-Week High?
What percentage is Ocugen Inc up from its 52-Week Low?
Current Price
$0.4
$0
(0%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.